Again, this might point to a particularly strong canonical WNT activity in the CRLM of poor-outcome patient I. It must be mentioned that TGFB1 can act both as a tumor suppressor and a tumor promoter, depending on the cellular context. This evidence concerns the gene TGFB1 and neoplasm.